Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Propranolol hydrochloride
Drug ID BADD_D01868
Description Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors.[L6904] Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.[L6904]
Indications and Usage Propranolol is indicated to treat hypertension.[L6907,L6904] Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.[L6904,L6907]
Marketing Status approved; investigational
ATC Code C07AA05
DrugBank ID DB00571
KEGG ID D00483
MeSH ID D011433
PubChem ID 62882
TTD Drug ID D04JEE
NDC Product Code 0121-0908; 42689-012; 50090-0146; 0228-2778; 0228-2781; 53002-4950; 62559-533; 63629-2279; 69238-2081; 70518-3377; 70518-3552; 71205-446; 0591-5554; 0591-5555; 0603-5484; 72162-1175; 0904-6705; 51604-0002; 69237-002; 0115-1661; 42689-014; 51407-236; 51655-426; 51662-1338; 51991-819; 60760-576; 63323-604; 63629-2278; 63629-3587; 0404-9944; 68382-161; 68382-162; 69238-2077; 69238-2080; 69292-536; 71205-760; 71205-794; 72789-280; 59917-095; 0115-1660; 42291-525; 42689-013; 43063-647; 43353-961; 51407-235; 53002-3600; 60687-598; 62559-530; 63629-2071; 63629-2277; 63629-9282; 0378-0182; 65841-746; 68071-2710; 69292-530; 69292-538; 0527-4119; 70518-3465; 70518-3466; 70518-3509; 71335-0082; 71335-0554; 71335-1765; 0603-5485; 71872-7096; 71872-7195; 72189-074; 53808-1126; 60687-215; 60687-226; 60760-262; 63629-2069; 63629-2072; 0378-0183; 68788-7350; 68788-7860; 69238-2079; 0527-4117; 70518-3281; 70934-581; 71335-0731; 71335-0955; 71335-1712; 0591-5557; 0603-5486; 0615-8426; 59917-094; 51407-239; 51655-864; 51991-820; 62559-521; 62559-523; 62559-532; 63629-2275; 68382-163; 68788-6855; 70518-1041; 71205-761; 71335-0472; 0904-6550; 0591-5556; 51927-1606; 42291-524; 50090-2756; 51407-238; 55700-940; 65841-745; 65841-748; 68788-7791; 70518-3141; 71205-185; 0615-8186; 0615-8187; 72162-1176; 22568-1027; 42816-0470; 42816-0473; 42816-0479; 49452-6089; 42291-523; 55289-233; 60687-587; 62559-522; 63629-2276; 63629-2280; 0378-0185; 0378-0187; 69238-2078; 70518-3102; 70934-922; 71335-0234; 0615-8413; 0615-8417; 0115-1662; 50090-0149; 51407-237; 51655-228; 51991-817; 60687-609; 60760-538; 62559-601; 65841-747; 0527-4116; 0527-4118; 70518-1831; 70934-997; 0054-3727; 0603-5483; 57451-1124; 59917-092; 0115-1659; 0228-2780; 53002-4951; 62559-590; 62559-600; 63187-839; 63629-2070; 63629-2274; 0378-0184; 64370-375; 69292-532; 69292-534; 70518-0164; 0054-3730; 71205-590; 71335-1120; 71610-339; 0603-5482; 72189-322; 57451-1128; 59917-093; 42291-522; 42689-011; 43353-084; 0143-9872; 50090-0148; 51655-302; 53002-4560; 55154-4162; 60760-545; 62559-520; 62559-531; 62559-591; 63629-2281; 63629-2282; 68382-164; 70518-1463; 70518-3053; 71205-499; 71335-1994; 42816-0471; 66219-0007; 51655-767; 0228-2779; 51991-818
UNII F8A3652H1V
Synonyms Propranolol | Propanolol | Inderal | Avlocardyl | AY-20694 | AY 20694 | AY20694 | Rexigen | Dexpropranolol | Dociton | Obsidan | Obzidan | Propranolol Hydrochloride | Hydrochloride, Propranolol | Anaprilin | Anapriline | Betadren
Chemical Information
Molecular Formula C16H22ClNO2
CAS Registry Number 318-98-9
SMILES CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mesenteric artery thrombosis24.01.08.003; 07.15.02.008--Not Available
Nausea07.01.07.001--
Oculomucocutaneous syndrome23.03.01.022; 07.05.01.010; 06.04.05.014--Not Available
Paraesthesia17.02.06.005; 23.03.03.094--
Peyronie's disease21.12.01.002--Not Available
Pharyngitis11.01.13.003; 22.07.03.004; 07.05.07.004--
Psoriasis23.03.14.002; 10.02.01.036--Not Available
Pyrexia08.05.02.003--
Rash erythematous23.03.13.029--Not Available
Respiratory distress22.02.01.012--Not Available
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.003--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Urticaria23.04.02.001; 10.01.06.001--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Affect lability19.04.01.001--Not Available
Purpura non-thrombocytopenic01.01.04.006--Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
Arterial insufficiency24.04.02.005--Not Available
Neuropsychological test abnormal13.07.06.001--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
The 2th Page    First    Pre   2    Total 2 Pages